Biomarkers in vascular dementia: A recent update

Biomarkers and Genomic Medicine

Volumn 7, Issue 2, 2015, Pages 43-56

  Jagtap, Abhijeet ^a   Gawande, Sonal ^a   Sharma, Sushil ^a  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

Cerebrospinal fluid; Charnoly body; Neuroimaging; Serum

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; C REACTIVE PROTEIN; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; METALLOTHIONEIN; MICRORNA; NITRIC OXIDE SYNTHASE; NOTCH3 RECEPTOR; SCAVENGER; TAU PROTEIN; ZINC;

BIOENERGY; CADASIL; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL THERAPY; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; GENETIC ANALYSIS; GENETIC RISK; HUMAN; MOLECULAR PATHOLOGY; MULTIINFARCT DEMENTIA; NEUROIMAGING; NEUROPROTECTION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

EID: 84931006327     PISSN: 22140247     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bgm.2014.11.001     Document Type: Review

References (89)

1. Mills S., Cain J., Purandare N., et al. Biomarkers of cerebrovascular disease in dementia. Br J Radiol 2007, 80:S128-S145.
2. Kirshner H.S. Vascular dementia: A review of recent evidence for prevention and treatment. Curr Neurol Neurosci Rep 2009, 9:437-442.
3. Shoji M. Biomarkers of the dementia. Int J Alzheimers Dis 2011, 564321.
4. Ray L., Khemka V., Behera P., et al. Serum homocysteine, dehydroepiandrosterone sulphate and lipoprotein (a) in Alzheimer's disease and vascular dementia. Aging Dis 2013, 4:57-64.
5. Simonsen A.H., Hagnelius N.O., Waldemar G., et al. Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease. Int J Proteomics 2012, 824024.
6. Formichi P., Parnetti L., Radi E., et al. CSF biomarkers profile in CADASIL-a model of pure vascular dementia: usefulness in differential diagnosis in the dementia disorder. Int J Alzheimers Dis 2010, 959257.
7. Legge S.D., Hachinski V. Vascular cognitive impairment (VCI) Progress towards knowledge and treatment. Dement Neuropsychol 2010, 4:4-13.
8. Chui H.C., Zarow C., Mack W.J., et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol 2006, 60:677-687.
9. Giannakopoulos P., Gold G., Kovari E., et al. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol 2007, 113:1-12.
10. Grinberg L.T., Heinsen H. Toward a pathological definition of vascular dementia. J Neurol Sci 2010, 299:136-138.
11. Román G.C., Tatemichi T.K., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993, 43:250-260.
12. Chui H.C., Victoroff J.I., Margolin D., et al. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992, 42:473-480.
13. Wetterling T., Kanitz R.D., Borgis K.J. Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996, 27:30-36.
14. Erkinjuntti T., Gauthier S. The concept of vascular cognitive impairment. Front Neurol Neurosci 2009, 24:79-85.
15. Forette F., Seux M., Staessen J.A., et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998, 352:1347-1351.
16. Shumaker S.A., Legault C., Rapp S.R., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2651-2652.
17. Rapp S.R., Espeland M.A., Shumaker S.A., et al. Effect of estrogen plus progestin on global cognitive function in post menopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2663-2672.
18. Quinn T.J., Gallacher J., Deary I.J., et al. Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes. J Thromb Haemost 2011, 9:1475-1482.
19. Pluta R., Ulamek M., Jablonski M. Alzheimer's mechanisms in ischemic brain degeneration. Anat Rec (Hoboken) 2009, 292:1863-1881.
20. Kaerst L., Kuhlmann A., Wedekind D., et al. Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: a critical analysis. J Neurol 2013, 260:2722-2727.
21. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011, 29:26-32.
22. Pantoni L., Sarti C., Alafuzoff I., et al. Postmortem examination of vascular lesions in cognitive impairment: a survey among neuropathological services. Stroke 2006, 37:1005-1009.
23. Wardlaw J.M., Sandercock P.A., Dennis M.S., et al. Is breakdown of the bloodbrain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?. Stroke 2003, 34:806-812.
24. Leblanc G.G., Meschia J.F., Stuss D.T., et al. Genetics of vascular cognitive impairment. the opportunity and the challenges. Stroke 2006, 37:248-255.
25. Tullberg M., Månsson J.E., Fredman P., et al. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 2000, 69:74-81.
26. Fredman P., Wallin A., Blennow K., et al. Sulfatide as a biochemical marker in cerebrospinal fluid of patients with vascular dementia. Acta Neurol Scand 1992, 85:103-106.
27. Wallin A., Sjögren M. Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Ageing Dev 2001, 122:1937-1949.
28. Galvin J.E. Dementia screening, biomarkers and protein misfolding. Implications for public health and diagnosis. Prion 2011, 5:16-21.
29. Rosenberg G.A., Sullivan N., Esiri M.M. White matter damage is associated with matrix metalloproteinases in vascular dementia. Stroke 2001, 32:1162-1168.
30. Liuzzi G.M., Trojano M., Fanelli M., et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: Implication for pathogenesis. Mult Scler 2002, 8:222-228.
31. Hagnelius N., Wahlund L., Nilsson T. CSF/serum folate gradient: physiology and determinants with special reference to dementia. Dement Geriatr Cogn Disord 2008, 25:516-523.
32. Paraskevas G.P., Kapok E., Papageorgiou S.G., et al. CSF biomarker profile and diagnostic value in vascular dementia. Euro J Neurol 2009, 16:205-211.
33. Thaweepoksomboon J., Senanarong V., Poungvarin N., et al. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. J Med Assoc Thai 2011, 94:S77-S83.
34. Pluta R., Jolkkonen J., Cuzzocrea S., et al. Cognitive impairment with vascular impairment and degeneration. Curr Neurovasc Res 2011, 8:342-350.
35. Schoonenboom N., Reesink F., Verwey N., et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012, 78:47-54.
36. Olsson B., Hertze J., Ohlsson M., et al. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. J Alzheimers Dis 2013, 34:673-679.
37. Chacón I.J., Molero A.E., Pino-Ramírez G., et al. Risk of dementia associated with elevated plasma homocysteine in a Latin American population. Int J Alzheimers Dis 2009, 632489.
38. Malaguarnera M., Ferri R., Bella R., et al. Homocysteine, vitamin B12 and folate in vascular dementia and in Alzheimer disease. Clin Chem Lab Med 2004, 42:1032-1035.
39. Den Heijer T., Vermeer S.E., Clarke R., et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003, 126:170-175.
40. Aisen P.S., Schneider L.S., Sano M., et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008, 300:1774-1783.
41. Tsimikas S., Hall J.L. Lipoprotein (a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012, 60:716-721.
42. Berglund L., Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004, 24:2219-2226.
43. Naylor J.C., Hulette C.M., Steffens D.C., et al. Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. J Clin Endocrinol Metab 2008, 93:3173-3178.
44. Aldred S., Mecocci P. Decreased dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) concentrations in plasma of Alzheimer's disease (AD) patients. Arch Gerontol Geriatr 2010, 51:e16-e18.
45. Kurata K., Takebayashi M., Morinobu S., et al. β-estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate protect against N-methyl-D-aspartate-induced neurotoxicity in rat hippocampal neurons by different mechanisms. J Pharmacol Exp Ther 2004, 311:237-245.
46. Forti P., Olivelli V., Rietti E., et al. Serum thyroid-stimulating hormone as a predictor of cognitive impairment in an elderly cohort. Gerontology 2012, 58:41-49.
47. Hamaguchi T., Yamada M. Genetic factors for cerebral amyloid angiopathy. Brain Nerve 2008, 60:1275-1283. [Article in Japanese].
48. Geroldi D., Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006, 13:1971-1978.
49. Casserly I., Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol and misfolded proteins. Lancet 2004, 363:1139-1146.
50. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology group of the Medical Research Council Cognitive Function and Ageing Study (MRC-CFAS). Lancet 2001, 357:169-175.
51. Debette S., Seshadri S. Genetics of atherothrombotic and lacunar stroke. Circ Cardiovasc Genet 2009, 2:191-198.
52. Forti P., Pisacane N., Rietti E., et al. Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc 2010, 58:487-492.
53. Marchesi V.T. Alzheimer's disease and CADASIL are heritable, adult-onset dementias that both involve damaged small blood vessels. Cell Mol Life Sci 2014, 71:949-955.
54. Gridley T. Notch signaling in vascular development and physiology. Development 2007, 134:2709-2718.
55. Haritunians T., Chow T., De Lange R.P.J., et al. Functional analysis of a recurrent missense mutation in Notch3 in CADASIL. J Neurol Neurosurg Psychiatry 2005, 76:1242-1248.
56. Lo E.H., Dalkara T., Moskowitz M.A. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003, 4:399-415.
57. Rosenstein J.M., Krum J.M. New roles for VEGF in nervous tissue-beyond blood vessels. Exp Neurol 2004, 187:246-253.
58. Emanuele E., Lista S., Ghidoni R., et al. Chromosome 9p21.3 genotype is associated with vascular dementia and Alzheimer's disease. Neurobiol Aging 2011, 32:1231-1235.
59. Visvikis-Siest S., Marteau J.B. Genetic variants predisposing to cardiovascular disease. Curr Opin Lipidol 2006, 17:139-151.
60. Battistin L., Cagnin A. Vascular cognitive disorder. A biological and clinical overview. Neurochem Res 2010, 35:1933-1938.
61. Sheinerman K.S., Tsivinsky V.G., et al. Plasma microRNA biomarkers for detection of mild cognitive impairment. Aging 2012, 4:590-605.
62. Yamacuchi M. MicroRNAs in vascular biology. Int J Vasc Med 2012, 1-12. Manuscript I.D # 794898.
63. Ungvari Z., Tucsek Z., Sosnowska D., et al. Aging induced dysregulation of dicer1-dependent microRNA expression impairs angiogenic capacity of rat cerebromicrovascular endothelial cells. J Gerontol A Biol Sci Med Sci 2013, 68:877-891.
64. Brenneman M., Sharma S., Harting M., et al. Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J Cereb Blood Flow Metab 2010, 30:140-149.
65. Sharma S., Ebadi M. Metallothioneins as early and sensitive biomarkers of redox signaling in neurodegenerative disorders. IIOAB J 2011, 2:98-106.
66. Sharma S., Ebadi M. Therapeutic potential of metallothioneins as antiinflammatory agents in polysubstance abuse. IIOAB J 2011, 2:50-61.
67. Sharma S., Yang B., Xi X., et al. IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain Res 2011, 1373:189-194.
68. Yang B., Strong R., Sharma S., et al. Therapeutic time window and dose-response of autologous bone marrow mononuclear cells for ischemic stroke. J Neurosci Res 2010, 89:833-839.
69. Sharma A., Badhe P., Gokulchandran N., et al. Autologous bone marrow derived mononuclear cell therapy for vascular dementia. J Stem Cell Res Ther 2012, 2:129.
70. Doring Y., Noels H., Weber C. The use of high-throughput technologies to investigate vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012, 32:182-195.
71. Cochrane Dementia and Cognitive Improvement Group Cerebrolysin for Vascular Dementia. The Cochrane Collaboration 2013, John Wiley & Sons, Ltd., London. N. Chen, M. Yang, J. Guol, M. Zhoul, C. Zhu, L. He (Eds.).
72. Vitali P., Migliaccio R., Agosta F., et al. Neuroimaging in dementia. Semin Neurol 2008, 28:467-483.
73. Hachinski V. The 2005 Thomas Willis Lecture: stroke and vascular cognitive impairment: a transdisciplinary, translational and transactional approach. Stroke 2007, 38:1396.
74. Sharma S., Ebadi M. Antioxidant Targeting in Neurodegenerative Disorders 2014, vol. 85:1-30. Springer Verlag, Berlin.
75. Sharma S., Ebadi M. Significance of metallothioneins in aging brain. Neurochem Int 2014, 65:40-48.
76. Sharma S., Rais A., Sandhu R., et al. Clinical significance of metallothioneins in cell therapy and nanomedicine. Int J Nanomedicine 2013, 8:1477-1488.
77. Sharma S., Moon C.S., Khogali A., et al. Biomarkers of Parkinson's disease (Recent Update). Neurochem Int 2013, 63:201-229.
78. Sharma S. Charnoly body as a sensitive biomarker in nanomedicine 2013; July, 25-27. (Invited Speaker) International Translational Nanomedicine Conference, Boston.
79. Sharma S., Nepal B., Moon C.S., et al. Psychology of craving. Open J Med Psychol 2014, 3:120-125.
80. Sharma S. Molecular pharmacology of environmental neurotoxins. Kainic Acid: Neurotoxic Properties, Biological Sources, and Clinical Applications 2014, 46-93. Nova Science Publishers, New York.
81. O'Bryant S.E., Humphreys J.D., Smith G.E., et al. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol 2008, 65:963-967.
82. Oosterman J.M., Scherder E.J. Distinguishing between vascular dementia and Alzheimer's disease by means of the WAIS: a meta-analysis. J Clin Exp Neuropsychol 2006, 28:1158-1175.
83. Donnell A.J., Pliskin N., Holdnack J., et al. Rapidly administered short forms of the Wechsler Adult Intelligence Scale-3rd edition. Arch Clin Neuropsychol 2007, 22:917-924.
84. Pantoni L., Inzitari D. Hachinski's ischemic score and the diagnosis of vascular dementia: a review. Ital J Neurol Sci 1993, 14:539-546.
85. Moroney J.T., Bagiella E., Desmond D.W., et al. Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology 1997, 49:1096-1105.
86. Risberg J., Passant U., Warkentin S., et al. Regional cerebral blood flow in frontal lobe dementia of non-Alzheimer type. Dementia 1993, 4:186-187.
87. Passant U., Warkentin S., Gustafson L. Orthostatic hypotension and low blood pressure in organic dementia: a study of prevalence and related clinical characteristics. Int J Geriatr Psychiatry 1997, 12:395-403.
88. Passant U., Warkentin S., Karlson S., et al. Orthostatic hypotension in organic dementia: relationship between blood pressure, cortical blood flow and symptoms. Clin Auton Res 1996, 6:29-36.
89. Atwood L.D., Wolf P.A., Heard-Costa N.L., et al. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 2004, 35:1609-1613.